Thoratec HeartMate VE LVAS Cuts Mortality Rate By 27% At One Year
This article was originally published in The Gray Sheet
Executive Summary
A 52% one-year survival rate for patients implanted with the Thoratec HeartMate VE represents a 27% improvement over medical therapy for end-stage heart failure when the left ventricular assist system is used as an alternative to transplant